Latest News

AbbVie: Not yet on Venclexta but future is positive April 23, 2018

AbbVie has decided against progressing a recommendation by the Pharmaceutical Benefits Advisory Committee for the listing of VENCLEXTA (venetoclax).

A proud industry committed to doing the right thing April 23, 2018

There is no doubting the extent of the challenge faced by the Board of directors of any organisation in balancing their company interest with that of the wider industry and their legal obligations as directors.

March PBAC outcomes April 23, 2018

Publication of the outcomes from the March PBAC meeting has revealed some major recommendations and significant rejections, with biosimilars featuring prominently and even a special pricing arrangement.

GBMA confirms biosimilar education grant April 23, 2018

The Generic and Biosimilar Medicines Association has secured its $5.5 million Biosimilar Educational Grant.

Mayne officially opens US facility April 20, 2018

Australian company Mayne Pharma has officially opened its new $80-million, oral solid-dose commercial manufacturing facility in the US state of North Carolina.

The question is how and why now? April 20, 2018

The Department of Health says PBAC makes recommendations based on legislated requirements but the criteria for granting a special pricing arrangement are administrative. They are absolutely correct but the question is why apply discretion now?

New report show rebates average 44% in New Zealand April 20, 2018

The association representing the country's research-based pharmaceutical industry has released its latest medicines landscape.

Merck sells consumer health business April 20, 2018

German-based Merck has announced the US$4.2 billion sale of its consumer health business to Procter & Gamble.

Shire rejects third bid from Takeda April 20, 2018

Shire has confirmed it has rejected a US$63 billion takeover bid from Takeda while Allergan has ended its short-lived interest in the company.

PBS listing process descends into farce April 19, 2018

The PBS listing process has descended into virtual farce with officials actively offering companies inducements to list medicines on the condition they agree to be part of the rebate reform pilot.

Once contentious is now confusing April 18, 2018

Special pricing arrangements have been around for ten years but they have never been more contentious, or confusing.

Sanofi sells European generics business April 18, 2018

Sanofi has been engaged in a range of corporate activities in recent months, including the US$16 billion acquisition of biotechnology company Ablynx and haemophilia company Bioverativ.

Most Read

March PBAC outcomes

A proud industry committed to doing the right thing

AbbVie: Not yet on Venclexta but future is positive

GBMA confirms biosimilar education grant

New Stories

AbbVie: Not yet on Venclexta but future is positive

A proud industry committed to doing the right thing

March PBAC outcomes

GBMA confirms biosimilar education grant

Mayne officially opens US facility

The question is how and why now?

New report show rebates average 44% in New Zealand

Sign In

Most Read

March PBAC outcomes

A proud industry committed to doing the right thing

AbbVie: Not yet on Venclexta but future is positive

GBMA confirms biosimilar education grant

Follow Us

New Stories

AbbVie: Not yet on Venclexta but future is positive

A proud industry committed to doing the right thing

March PBAC outcomes

GBMA confirms biosimilar education grant

Mayne officially opens US facility

The question is how and why now?

New report show rebates average 44% in New Zealand